Table 2. Phase II/III trials targeting VEGFR in gastroesophageal cancers.
| Study | Phase | Setting | Treatment | Patients | PFS | OS |
|---|---|---|---|---|---|---|
| Shah et al. (61) | II | First line | Irinotecan, Cisplatin, and Bevacizumab | 47 | ORR: 6.5 mo | 12.3 mo |
| Ohtsu et al./ AVAGAST (55) | III | First line | Cisplatin/5FU ± Bevacizumab | 774 | 38.0 vs. 29.5 mo, P=0.0121 | 12.1 vs. 10.1 mo, P=1.002 |
| Fuchs et al./ REGARD (57) | III | Second line | Ramucirumab vs. BSC | 355 | 2.1 vs. 1.3 mo, P<0.0001 | 5.2 vs. 3.8 mo, P=0.047 |
| Wilke et al./ RAINBOW (59) | III | Second line | Paclitaxel ± Ramucirumab | 665 | 4.4 vs. 2.9 mo, P<0.0001 | 9.6 vs. 7.4 mo, P=0.017 |
| Yoon et al. (60) | II | First line | FOLFOX ± Ramucirumab | 168 | 6.4 vs. 6.7 mo, P=0.89 | 11.7 vs. 11.5 mo, P not available, HR 1.08, 95% CI, 0.73-1.58 |
VEGFR, vascular endothelial growth factor receptor; PFS, progression free survival; OS, overall survival; ORR, overall response rate; mo, months; 5FU, 5-fluorouracil; BSC, best supportive care; FOLFOX, 5-fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; CI, confidence interval.